- Home
- HOOK
HOOK
HOOKIPA Pharma Inc.
as 11-18-2024 4:00pm EST
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Upcoming Earnings Alert:
Get ready for potential market movements as HOOKIPA Pharma Inc. HOOK prepares to release earnings report on 22 Nov 2024.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 30.2M | IPO Year: | 2019 |
| Target Price: | $38.75 | AVG Volume (30 days): | 53.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.76 - $11.30 | Next Earning Date: | 11-22-2024 |
| Revenue: | $49,999,000 | Revenue Growth: | 227.80% |
| Revenue Growth (this year): | 155.36% | Revenue Growth (next year): | -50.39% |
Latest HOOKIPA Pharma Inc. News
HOOK Breaking Stock News: Dive into HOOK Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
Simply Wall St.
2 days ago
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
4 days ago
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
GlobeNewswire
7 days ago
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
GlobeNewswire
19 days ago
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
GlobeNewswire
20 days ago
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
GlobeNewswire
2 months ago
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
Zacks
3 months ago
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
Compare HOOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HOOK HOOKIPA Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.